Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas

A Shikama, T Minaguchi, K Matsumoto… - Gynecologic …, 2016 - Elsevier
Objective Endometrial carcinoma is the most common malignancy in women with Lynch
syndrome caused by mismatch repair (MMR) deficiency. We investigated the …

Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT study): an open-label, multicenter, randomized …

Y Yamashita, T Morimoto, N Muraoka, T Oyakawa… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep
vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The …

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

N Tasaka, T Minaguchi, Y Hosokawa… - Journal of Obstetrics …, 2020 - Wiley Online Library
Aim Postoperative pulmonary embolism can be a fatal surgical complication and is thought
to occur secondary to asymptomatic venous thromboembolism (VTE) that exists …

[HTML][HTML] PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas

S Zhang, T Minaguchi, C Xu, N Qi, H Itagaki… - Bmc Cancer, 2020 - Springer
Background Tumor microenvironment (TME) including the immune checkpoint system
impacts prognosis in some types of malignancy. The aim of our study was to investigate the …

[HTML][HTML] Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the …

I Vergote, I Ray-Coquard, DM Anderson… - European Journal of …, 2021 - Elsevier
Background In the absence of randomised head-to-head trials, we conducted a population-
adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative …

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775

K Yonemori, M Yunokawa, K Ushijima… - Cancer …, 2022 - Wiley Online Library
Abstract Study 309/KEYNOTE‐775 is a phase 3 open‐label, randomized trial of lenvatinib
plus pembrolizumab versus treatment of physician's choice (TPC) in patients with advanced …

[HTML][HTML] Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma

A Akiyama, T Minaguchi, K Fujieda… - Oncology …, 2019 - spandidos-publications.com
Type II endometrial carcinoma mainly originates from p53 aberration. However, the detailed
prognostic significance of p53 aberration in endometrial carcinoma remains to be clarified …

Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism

M Sakurai, K Matsumoto, M Gosho, A Sakata… - International Journal of …, 2017 - ijgc.bmj.com
Objectives Our 2007 study of 32 patients with ovarian cancer reported the possible
involvement of tissue factor (TF) in the development of venous thromboembolism (VTE) …

Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer

A Shikama, T Minaguchi, W Takao, Y Hosokawa… - International Journal of …, 2019 - Springer
Objective The selection criteria for secondary cytoreductive surgery (SCS) for recurrent
endometrial cancer (EC) remain to be defined. The present study aimed to identify predictors …

[HTML][HTML] Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin

B Lachkar, T Minaguchi, A Akiyama, S Liu, S Zhang… - Medicine, 2018 - journals.lww.com
The standard treatment for locally advanced cervical cancer is cisplatin-based concurrent
chemoradiotherapy (CCRT). Although the activated PI3-kinase/Akt pathway is known to be …